{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:13:38Z","timestamp":1788527618749,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001695","name":"International Waldenstroms Macroglobulinemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100271","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:13:42Z","timestamp":1784218422000},"page":"100271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment preferences in Waldenstr\u00f6m macroglobulinemia: an international discrete choice experiment in 1455 patients"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2942-9385","authenticated-orcid":false,"given":"Anne-Marie L.","family":"Becking","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2616-1414","authenticated-orcid":false,"given":"Pythia T.","family":"Nieuwkerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Postek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Amaador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie J.","family":"Bernelot Moens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bronsgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Faubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-0639","authenticated-orcid":false,"given":"Ibrahim","family":"Tohidi-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Warden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-9556","authenticated-orcid":false,"given":"Josephine M. I.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Freese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna R.","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"van der Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"El-Sharkawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Ternoway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2026.100271_bib1","series-title":"WHO Classification of Tumours, 5th Edition 2022: Haematolymphoid Tumours Part B","author":"Naresh","year":"2024"},{"issue":"2","key":"10.1016\/j.bneo.2026.100271_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of consensus panel 4 from the 11th International Workshop on Waldenstrom\u2019s macroglobulinemia on diagnostic and response criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100271_bib3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","article-title":"Waldenstr\u00f6m's macroglobulinemia: incidence patterns in the United States, 1988-1994","volume":"82","author":"Groves","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2026.100271_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.leukres.2007.02.002","article-title":"The incidence and survival of Waldenstr\u00f6m's macroglobulinaemia in South East England","volume":"32","author":"Phekoo","year":"2008","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.bneo.2026.100271_bib5","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.bneo.2026.100271_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstr\u00f6m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100271_bib7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3109\/10428194.2012.656103","article-title":"Waldenstr\u00f6m macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005","volume":"53","author":"Sekhar","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.bneo.2026.100271_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2023.03.005","article-title":"Report of consensus panel 1 from the 11(th) International Workshop on Waldenstrom's macroglobulinemia on management of symptomatic, treatment-na\u00efve patients","volume":"60","author":"Buske","year":"2023","journal-title":"Semin Hematol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100271_bib9","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstr\u00f6m macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy","volume":"100","author":"Kastritis","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bneo.2026.100271_bib10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17856","article-title":"Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinaemia: a population-based study in the Netherlands, 1989-2018","volume":"196","author":"Amaador","year":"2022","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.bneo.2026.100271_bib11","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3390\/cancers17223609","article-title":"Patient perception of the relevance of quality-of-life questionnaires in Waldenstr\u00f6m macroglobulinaemia: an international survey","volume":"17","author":"Khwaja","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bneo.2026.100271_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221093962","article-title":"Treatment paradigm in Waldenstr\u00f6m macroglobulinemia: frontline therapy and beyond","volume":"13","author":"Zanwar","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100271_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clml.2022.02.005","article-title":"SOHO State of the Art Updates and Next Questions: targeted therapies and emerging novel treatment approaches for Waldenstr\u00f6m macroglobulinemia","volume":"22","author":"Sermer","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.bneo.2026.100271_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.seminhematol.2023.03.003","article-title":"Report of consensus panel 2 from the 11th International Workshop on Waldenstr\u00f6m's macroglobulinemia on the management of relapsed or refractory WM patients","volume":"60","author":"D'Sa","year":"2023","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100271_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.seminhematol.2025.05.001","article-title":"Insights from the 12(th) International Workshop on Waldenstrom's macroglobulinemia","volume":"62","author":"Treon","year":"2025","journal-title":"Semin Hematol"},{"issue":"33","key":"10.1016\/j.bneo.2026.100271_bib16","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100271_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m's macroglobulinemia: final analysis from the randomized phase III iNNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.bneo.2026.100271_bib18","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2026.100271_bib19","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100271_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100271_bib22","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2025-3583","article-title":"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study","volume":"146","author":"Tam","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100271_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2025-226","article-title":"Pirtobrutinib in relapsed\/refractory (R\/R) Waldenstr\u00f6m macroglobulinemia (WM): up to 5 years of follow-up from the phase 1\/2 BRUIN study","volume":"146","author":"Cheah","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100271_bib24","article-title":"BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstr\u00f6m macroglobulinemia","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100271_bib25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2024-200604","volume":"144","author":"Buske","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2026.100271_bib26","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1185\/03007995.2014.952715","article-title":"Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model","volume":"30","author":"Shingler","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.bneo.2026.100271_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14737167.2019.1612242","article-title":"The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management","volume":"19","author":"Jackson","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.bneo.2026.100271_bib28","series-title":"Benefit-Risk Assessment for New Drug and Biological Products","year":"2023"},{"key":"10.1016\/j.bneo.2026.100271_bib29","series-title":"Reflection Paper on Patient Experience Data","year":"2025"},{"issue":"7436","key":"10.1016\/j.bneo.2026.100271_bib30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","article-title":"Discrete choice experiments in health care","volume":"328","author":"Ryan","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.bneo.2026.100271_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hec.1697","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"21","author":"de Bekker-Grob","year":"2012","journal-title":"Health Econ"},{"issue":"9","key":"10.1016\/j.bneo.2026.100271_bib32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"32","author":"Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100271_bib33","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1182\/blood-2023-178754","article-title":"Patient preference studies in hematologic malignancies: a systematic review","volume":"142","author":"Richardson","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100271_bib34","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1002\/cam4.5080","article-title":"Patient preferences regarding treatment options for Waldenstr\u00f6m\u2019s macroglobulinemia: a discrete choice experiment","volume":"12","author":"Amaador","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100271_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force","volume":"16","author":"Reed Johnson","year":"2013","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.bneo.2026.100271_bib36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.bneo.2026.100271_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.bneo.2026.100271_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.113822","article-title":"To pay or not to pay? Cost information processing in the valuation of publicly funded healthcare","volume":"276","author":"Genie","year":"2021","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.bneo.2026.100271_bib39","series-title":"DCREATE: Stata Module to Create Efficient Designs for Discrete Choice Experiments","author":"Hole","year":"2015"},{"issue":"5-6","key":"10.1016\/j.bneo.2026.100271_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000360992","article-title":"Outcome disparities among ethnic subgroups of Waldenstr\u00f6m's macroglobulinemia: a population-based study","volume":"86","author":"Ailawadhi","year":"2014","journal-title":"Oncology"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100271_bib41","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2021-153590","article-title":"Ethnic disparities in Waldenstr\u00f6m's macroglobulinaemia in the United Kingdom - analysis from the WMUK Rory Morrison Registry","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2026.100271_bib42","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3324\/haematol.2024.285420","article-title":"Ethnic diversity in presentation and outcome of Waldenstr\u00f6m macroglobulinemia and IgM monoclonal gammopathy of clinical significance in the United Kingdom","volume":"109","author":"Khwaja","year":"2024","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bneo.2026.100271_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","article-title":"Sample size requirements for discrete-choice experiments in healthcare: a practical guide","volume":"8","author":"de Bekker-Grob","year":"2015","journal-title":"Patient"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100271_bib44","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1182\/blood-2023-177690","article-title":"Patient and physician preferences for fixed-duration vs treatment to progression chronic lymphocytic leukemia (CLL) treatments: results from a multi-country discrete choice experiment","volume":"142","author":"Sile","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100271_bib45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2147\/PPA.S510401","article-title":"Preferences for first-line chronic lymphocytic leukemia treatments: results from a multinational study on the perspectives of patients and physicians","volume":"19","author":"Sile","year":"2025","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.bneo.2026.100271_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1589722","article-title":"Patient and physician treatment preferences in relapsed\/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan","volume":"15","author":"Gribben","year":"2025","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100271_bib47","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1182\/blood-2025-3577","article-title":"Venetoclax or pirtobrutinib in relapsed\/refractory Waldenstr\u00f6m macroglobulinemia: clinical and molecular predictors and sequencing implications","volume":"146","author":"Guijosa","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2026.100271_bib48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.2023022420","article-title":"Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia","volume":"143","author":"Castillo","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100271_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102965","article-title":"Prediction accuracy of discrete choice experiments in health-related research: a systematic review and meta-analysis","volume":"79","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.bneo.2026.100271_bib50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.seminhematol.2023.03.008","article-title":"The epidemiology of Waldenstr\u00f6m macroglobulinemia","volume":"60","author":"McMaster","year":"2023","journal-title":"Semin Hematol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:21:10Z","timestamp":1788524470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026000828"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100271","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment preferences in Waldenstr\u00f6m macroglobulinemia: an international discrete choice experiment in 1455 patients","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100271"}}